Disruptive Technologies in Radiology & Nuclear Medicine - Phillip Koo

March 30, 2019

Phillip Koo and Alicia Morgans discuss disruptive changes impacting clinical practice. Clearly, medical practice disruptions occur more incrementally than when we think of what this means in consumer-based areas and yet each day new data from key clinical trials has the potential to shake up what is viewed-as the current standard of care. New data is challenging radiology and nuclear medicine as was experienced when reviewing the PRECISION trial results from early 2018. A key take-home message from the discussion is that quality improvement is essential within the local team performing the imaging studies, including the impact of high volume readers in reviewing test results. They also discuss PET in both the diagnosis of recurrent prostate cancer and treatment in men with disease progression. This discussion provides us direction for future considerations. Overall these disruptions in the diagnosis and future treatment of prostate cancer are all expected to positively impact patient outcomes. 


Phillip J. Koo, MD, FACS Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona.

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.